4.1.4.2.1. anticholinergic drugs. anticholinergic (antimuscarinic) drugs currently mainstay treatment oab. different agents vary pharmacological profiles, muscarinic receptor affinity modes action pharmacokinetic properties, lipid solubility half-life. panel sr identified twelve studies (11,179 women) comparing antimuscarinics placebo. antimuscarinics significantly effective placebo improving mean symptom score oabq, reducing daily frequency episodes, reducing daily urgency episodes uui episodes, increasing bladder functional capacity . sr established antimuscarinics caused significantly higher adverse events placebo including dry mouth, cognitive impairment, uti constipation . immediate-release (ir) anticholinergic preparations provide maximum dosage flexibility, including off-label on-demand use. immediate-release drugs greater risk adverse effects extended release (er) formulations differing pharmacokinetics. transdermal delivery system gel developed oxybutynin provide alternative formulations. balance, ir formulations tend associated adverse effects compared er formulations . network meta-analysis 128 rcts including genders comparing anticholinergics placebo anticholinergics revealed anticholinergics, except imidafenacin, showed reasonable cure improvement rates oab symptoms sexes . differences across drugs terms alteration symptoms small. cure uui deemed important outcome measure. table 1 shows summary findings sr rcts including women . agents showed superiority compared placebo, absolute size effect small. table 1: summary cure discontinuation rates anticholinergic drugs rcts drugno. studiesno. patientsrr (95% ci)(of curing ui)nnt (95% ci)(to achieve one cure ui)cure incontinencefesoterodine22,4651.3 (1.1–1.5)8 (5–17)oxybutynin (includes ir)49921.7 (1.3–2.1)9 (6–16)propiverine (includes ir)26911.4 (1.2–1.7)6 (4–12)solifenacin53041.5 (1.4–1.6)9 (6–17)tolterodine (includes ir)43,4041.2 (1.1–1.4)12 (8–25)trospium (includes ir)42,6771.7 (1.5–2.0)9 (7–12)discontinuation due adverse eventsrr (95% ci)(of discontinuation)nnt (95% ci)(for one discontinuation)darifenacin73,1381.2 (0.8–1.8)fesoterodine44,4332.0 (1.3–3.1)33 (18–102)oxybutynin (includes ir)51,4831.7 (1.1–2.5)16 (8–86)propiverine (includes ir)21,4012.6 (1.4–5)29 (16–77)solifenacin79,0801.3 (1.1–1.7)78 (39–823)tolterodine (includes ir)104,4661.0 (0.6–1.7)trospium (includes ir)63,9361.5 (1.1–1.9)56 (30–228) ci = confidence interval; ir = immediate release; nnt = number treat; rr = relative risk;ui = urinary incontinence. cure rates darifenacin included us agency healthcare research quality (ahrq) review. continence rates 29–33% darifenacin compared 17–18% placebo . transdermal oxybutynin showed significant improvement compared placebo oral formulations number incontinence episodes micturitions per day cure ui reported outcome . oxybutynin topical gel superior placebo improvement uui, higher proportion participants cured .